68Ga-PSMA-617 PET/CT for PSMA-expressing Tumor: a Pragmatic Study

Launched by CENTRE DE RECHERCHE DU CENTRE HOSPITALIER UNIVERSITAIRE DE SHERBROOKE · Jan 27, 2022

Keywords

ClinConnect Summary

This clinical trial is studying a special type of imaging called 68Ga-PSMA-617 PET/CT, which helps doctors see certain tumors that express a protein called PSMA. While this imaging technique is commonly used for prostate cancer, the study is exploring its usefulness for other solid tumors as well. The goal is to find out if this imaging method is safe and how it can help doctors in managing patients with various types of solid cancers.

To participate in this trial, you need to be referred by a doctor for the 68Ga-PSMA-617 PET/CT scan and have a tumor that expresses PSMA. If you agree to join, you will receive this imaging, and researchers will monitor how it affects your treatment. It’s important to know that if you have previously had a severe allergic reaction to this imaging agent, you won't be able to participate. Overall, this study aims to see if this new imaging can become a standard part of cancer care, helping doctors make better decisions for their patients.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Clinical requisition for a 68Ga-PSMA-617 PET/CT signed by a referring doctor;
• • 2. Patients with suspected, proven or prior tumor expressing PSMA;
• • 3. Informed consent by patient.
• Exclusion Criteria:
• • 1. Patient refusal to participate;
• • 2. Prior severe anaphylactic reaction to 68Ga-PSMA-617 .